Navigation Links
Quintiles Appoints Christopher Cabell to Chief Medical and Scientific Officer
Date:6/6/2008

RESEARCH TRIANGLE PARK, N.C., June 6 /PRNewswire/ -- Quintiles Transnational Corp. today announced the appointment of Christopher H. Cabell, M.D., MHS, FACC, as Chief Medical and Scientific Officer. Cabell succeeds Oren Cohen, M.D., who was recently appointed Senior Vice President, Clinical Research Strategies.

As Chief Medical and Scientific Officer, Cabell will be responsible for company-wide initiatives that focus on bioethics and the protection of human subjects. In addition, he will be responsible for developing initiatives that bring forward innovations in medicine, science and technology into future business models.

Most recently, Cabell held the position of Global Cardiovascular / Endocrine Therapeutic Group Leader within the Medical and Scientific Services group and provided cardiology expertise for Quintiles Electrocardiogram (ECG) Services. In 2007, Cabell joined Quintiles from the Duke University School of Medicine, where he developed a strong background in clinical research. He held several appointments within the Duke Clinical Research Institute (DCRI), including Co-Chair and Principal Investigator for a Duke/FDA Cardiac Safety partnership to develop a new generation of tools to identify the potential effects of medical devices and drugs on the heart. Also within DCRI, he held appointments as Director of the Echocardiography Core Laboratory, Associate Director of the ECG Core Laboratory and Director of the International Collaboration on Endocarditis. He also was Assistant Professor of Medicine in the Division of Cardiology.

Cabell has authored or co-authored 50 articles for peer-reviewed publications and delivered more than 30 invited lectures. He is a member of several professional organizations, a Fellow of the American College of Cardiology, and a reviewer for a number of medical journals, including the Journal of the American Medical Association. He earned his medical degree and a Master's in Health Science from the Duke University School of Medicine.

About Quintiles

Quintiles Transnational Corp. is powering the next generation of healthcare by providing a broad range of professional services in drug development, commercialization and strategic partnering for the pharmaceutical, biotechnology and medical device industries. With more than 21,000 employees and offices in more than 50 countries, it is focused on providing customer-centric solutions that are the gold standard of the industry. For more information, please visit the company's Web site at http://www.qtrn.com


'/>"/>
SOURCE Quintiles Transnational Corp.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Michael Troullis Appointed Chief Financial Officer of Quintiles Transnational Corp.
2. Expert Cardiologist Joins Quintiles Medical Group
3. Quintiles Names Kelly McKee Executive Director of Operations for Public Health and Government Services Unit
4. Quintiles Central Lab, Clinical Development in China to Expand, Relocate to New Facility
5. Quintiles to Open Clinical Research Office in Wilmington, NC
6. Quintiles Completes Previously Announced New Investor Partnership, Co-Led by Founder, Chairman and CEO Dennis Gillings, Bain Capital, TPG and 3i
7. Quintiles Consulting Business Expands
8. Quintiles Signs Agreement to Acquire Eidetics
9. BioVex Appoints Dr. Thaddeus Pullano as VP, Quality Assurance
10. Codexis Appoints Singapore Laboratories Managing Director
11. Emisphere Technologies, Inc. Appoints Paul Lubetkin as Vice President and General Counsel
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... SAN FRANCISCO , Feb. 24, 2017 ... that is developing a new category of therapeutics, announced ... trial of SB-030 in peripheral artery disease. The trial ... locally administered single-use therapeutic, in the reduction of restenosis ... reached this critical development milestone for SB-030," said ...
(Date:2/24/2017)... China Cord Blood Corporation (NYSE: CO ) ... blood collection, laboratory testing, hematopoietic stem cell processing and ... results for the third quarter and first nine months ... Third Quarter of Fiscal 2017 Highlights ... increased by 18.6% to RMB200.9 million ($28.9 million). ...
(Date:2/24/2017)... -- China Biologic Products, Inc. (NASDAQ: CBPO) ("China Biologic" or ... China, today announced its financial results for the fourth quarter ... 2016 Financial Highlights Total sales in ... terms, or increased by 13.6% in USD terms to $77.6 ... Gross profit increased by 13.3% to $46.8 ...
(Date:2/24/2017)... , Feb. 24, 2017  OncoSec Medical Incorporated ("OncoSec") ... will host a Key Opinion Leader event to highlight ... oral and poster presentation at the upcoming 2017 ASCO-SITC ... KOL event will be held in-person and via live ... / 9:00 AM PST at the Lotte New York ...
Breaking Biology Technology:
(Date:1/24/2017)... 2017  It sounds simple and harmless—an electronic ... vital signs and alerts parents on their smart ... level drops. But pediatric experts argue that such ... no evidence of medical benefits, especially to healthy ... to parents of healthy babies, promising peace of ...
(Date:1/19/2017)... PORTLAND, Oregon and PUNE, India , January 19, ... Market Research, titled, "Global Biometric Sensor Market, Opportunities and Forecast, 2014 - ... 2022, growing at a CAGR of 9.6% from 2016 to 2022. In 2015, ... share owing to high-level security for both public and private sectors. ... ...
(Date:1/18/2017)... MINNETONKA, Minn. , Jan. 18, 2017 /PRNewswire/ ... eClinical technology company that supports the entire spectrum ... 2016 has been another record-breaking year for the ... and market interest in MedNet,s eClinical products and ... to the tremendous marketplace success of ...
Breaking Biology News(10 mins):